

RISE Talks Series

- Who?** Louis Lombardo, Group Director, Oncology Chemistry, Bristol-Myers Squibb
- What?** Discovery of SPRYCEL[®], A Multi-targeted Kinase Inhibitor with Potent Anti-tumor Activity in Preclinical Assays
- When?** 12:00-1:00 on Wednesday, February 14
- Where?** Hall of Sciences, Room 326

SPRYCEL[®], a small molecule kinase inhibitor, is a Bristol-Myers Squibb drug approved for the treatment of chronic myeloid leukemia (CML). Although it is marketed for an oncology indication, it was originally identified by the immunology therapeutic area as a potential treatment for autoimmune diseases. A case study on the discovery and clinical development of SPRYCEL[®] will be presented in this lecture.

Brief Bio:

Lou Lombardo received his Ph.D. in synthetic organic chemistry from Yale University under the direction of Professor Harry Wasserman. He received his B.A. in biochemistry from Drew University and was an inaugural participant in Drew's RISE program.